Clinical Trials and Research Studies

“Simultaneous knockdown of CD320 and LRP2 receptors is selectively toxic to cancer cells but not normal cells,” American Association of Cancer Research (AACR) Annual Meeting 2021, April-May, 2021

The presentation reports on research leading to selective killing of cancer cells without harm to normal cells. During efforts to elucidate the mechanism by which TCPP selectively accumulates in cancer cells, we discovered that simultaneous knock down of two LDLR-family receptors was selectively cytotoxic to cancer cells and not to normal cells.

read more

Identification of a novel mechanism for meso‐tetra (4‐carboxyphenyl) porphyrin (TCPP) uptake in cancer cells, Journal of the Federation of Societies for the Study of Experimental Biology (FASEB Journal), Feb. 25, 2021

The paper explains research that identified a novel mechanism by which the porphyrin TCPP, which is used in bioAffinity Technologies’ non-invasive test for the early detection of lung cancer, is incorporated into cancer cells using the cellular receptor CD320, which is involved in the uptake of Vitamin B12.

read more

Automated Flow Cytometry Test Distinguishes Cancer from Non-Cancer in Sputum with High Sensitivity and Specificity, International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer, Jan. 2021

The automated CyPath® Lung flow cytometric assay correctly classifies study participants into cancer or high risk cohorts with high accuracy, including participants with nodules smaller than 20 mm. The CyPath® Lung assay thus has the potential to complement LDCT screening and improve diagnosis of early stage lung cancer.

read more